Trademark: 88048381
Word
CYTOSEN THERAPEUTICS
Status Date
Monday, July 6, 2020
Filing Date
Monday, July 23, 2018
Published for Opposition
Tuesday, April 9, 2019
Abandoned Date
Monday, July 6, 2020
5 Pharmaceutical preparations for the treatment of immuno oncological disorders, cancer, diabetes, respiratory, heart, neurological and auto immune disorders; stem cells for medical purposes; living cells for medical use; biological preparations for the treatment of cancer; therapeutic pharmaceuticals utilizing neural crest cells for use in the treatment of cancer, autoimmune disease and infectious diseases; Cell preparations, cellular vaccines and cellular biologics for the treatment of cancer and infectious diseases by autologous cell-based immunotherapy
42 Scientific and technological services, namely, scientific research, design, analysis and testing in the field of cancer evolution and new cancer therapies using natural killer cells; industrial research in the field of new pharmaceutical products and new cancer therapies; medical and veterinary research services in the nature of the manipulation of cells within a laboratory or research facility to enable natural killer cells to be used for medical or therapeutic purposes; scientific research in the development of new cancer therapies; scientific research in human and animal cell therapy; scientific research into preparations for manipulating and adapting human and animal cells; consultancy relating to all the aforesaid services; Conducting research and clinical trials for others relating to the use and the engineering of natural killer cells and cancer treatment and therapy; medical and scientific research in the field of cancer treatment and diagnosis; data collection for others for research purposes, namely, the collection, testing and research of patient molecular and genomic data; collection and preservation of human and animal DNA for research purposes
44 Medical testing for diagnostic or treatment purposes in the field of cancer research; medical diagnostic testing, monitoring and reporting services; medical evaluation of immuno oncological disorders, cancer, diabetes, respiratory, heart, neurological and auto immune disorders; medical monitoring services; medical diagnostic, prognostic and theranostic screening and testing services; collection and preservation of dna for medical purposes; consulting services in the nature of providing medical information; consulting services in the field of healthcare and cancer diagnoses; providing a website featuring health and healthcare information related to cancer, testing and screening; genetic testing for medical purposes; providing information in the field of cancer prevention, screening, diagnosis and treatment for medical diagnostic and treatment purposes; providing genetics assessments in the nature of genetic counseling; genetic testing for medical diagnostic purposes; genomic testing for medical diagnostic purposes; Gene analysis and sequencing and DNA analysis and sequencing for medical diagnostic purposes and veterinary diagnostics purposes; gene analysis and sequencing and DNA analysis and sequencing for use in cancer diagnosis and treatment; providing a website featuring health and healthcare information related to cancer research
Color is not claimed as a feature of the mark.
"THERAPEUTICS"
The mark consists of the wording "CYTOSEN" in stylized text above the wording "THERAPEUTICS" in stylized text and to the right of a design consisting of a shaded circle inside of a partially-formed circle and six shaded circles of various sizes to the left of the partially-formed circle.
Dec 23, 2020
Automatic Update Of Assignment Of Ownership
Jul 6, 2020
Abandonment Notice E-Mailed - No Use Statement Filed
Jul 6, 2020
Abandonment - No Use Statement Filed
Dec 6, 2019
Notice Of Approval Of Extension Request E-Mailed
Dec 4, 2019
Extension 1 Granted
Dec 4, 2019
Extension 1 Filed
Dec 4, 2019
Teas Extension Received
Jun 4, 2019
Noa E-Mailed - Sou Required From Applicant
Apr 9, 2019
Official Gazette Publication Confirmation E-Mailed
Apr 9, 2019
Published For Opposition
Mar 20, 2019
Notification Of Notice Of Publication E-Mailed
Mar 15, 2019
Assigned To Petition Staff
Mar 5, 2019
Approved For Pub - Principal Register
Mar 5, 2019
Examiner's Amendment Entered
Mar 5, 2019
Notification Of Examiners Amendment E-Mailed
Mar 5, 2019
Examiners Amendment E-Mailed
Mar 5, 2019
Examiners Amendment -Written
Mar 4, 2019
Previous Allowance Count Withdrawn
Feb 26, 2019
Withdrawn From Pub - Og Review Query
Feb 13, 2019
Law Office Publication Review Completed
Feb 11, 2019
Assigned To Lie
Jan 28, 2019
Approved For Pub - Principal Register
Jan 23, 2019
Teas/Email Correspondence Entered
Jan 22, 2019
Correspondence Received In Law Office
Jan 22, 2019
Teas Response To Office Action Received
Nov 20, 2018
Notification Of Non-Final Action E-Mailed
Nov 20, 2018
Non-Final Action E-Mailed
Nov 20, 2018
Non-Final Action Written
Nov 8, 2018
Assigned To Examiner
Jul 27, 2018
Notice Of Design Search Code E-Mailed
Jul 26, 2018
New Application Office Supplied Data Entered In Tram
Jul 26, 2018
New Application Entered In Tram
Trademark Alertz updated from USPTO on 2030-01-24